SCHEMBL3938271

SCHEMBL3938271

Fc1ccc(-c2cc3ncnc(NCCc4c[nH]c5ccccc45)c3s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
GFER P55789 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
PDPK1 O15530 1/20 0.49
RPS6KB1 P23443 1/20 0.49
EGFR P00533 1/20 0.48
FLT1 P17948 1/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
USP2 O75604 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3937743 0.95 TYK2 (0.51) TYK2NPC1RAB9ALMNAMAPT
SCHEMBL4066406 0.88 LMNA (0.53) LMNAMAPTMAPK1HTTGFER
SCHEMBL4067717 0.87 FLT1 (0.54) LMNAMAPTMAPK1HTTGFER
SCHEMBL30162756 0.85 LMNA (0.53) LMNAMAPTMAPK1HTTGFER
SCHEMBL21996575 0.85 LMNA (0.53) LMNAMAPTMAPK1HTTGFER
SCHEMBL3929003 0.85 LMNA (0.49) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL4070386 0.85 PDPK1 (0.51) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3927158 0.84 CYP1A2 (0.63) LMNAMAPTMAPK1HTTGFER
SCHEMBL4070516 0.84 PDPK1 (0.52) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL4251177 0.83 FLT1 (0.51) LMNAMAPTMAPK1HTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20220251104-A1 AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS CELULARITY INC. (US) 2022-08-11 US disclosed
EP-3887364-A1 AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS Celularity Inc. (US) 2021-10-06 EP disclosed
CN-113454076-A Aromatic compounds for activating hematopoietic stem and progenitor cells 细胞结构公司 2021-09-28 CN disclosed
WO-2020113178-A1 AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS Celularity, Inc. (US) 2020-06-04 WO disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 TYK2 2539/4885NPC1 2246/4885RAB9A 3318/4885
US-20220251104-A1 AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS ALPP, MCL1, NFATC1 TYK2 2580/4885NPC1 3759/4885RAB9A 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.